BioMarin Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. Welcome. My name is Jess Fye, and we're continuing the 44th Annual JPMorgan Healthcare Conference with BioMarin. First, you're going to hear a presentation from the management team, and then we're going to go into some Q&A. (Operator Instructions)
Before we get started, I have to read this. It says, please note that JPMorgan has a role on the potential transaction involving Amicus and is subject to restrictions. As a result, I will not be discussing the transaction during the session or taking questions from the audience on that topic during Q&A. So with that out of the way, let me pass it over to BioMarin's CEO, Alexander Hardy, for the presentation.
Thank you very much, Jess, and thank you all for joining us this morning. Two years in the role as CEO of BioMarin. We've been busy as a team working on transforming BioMarin and setting the path for another era of significant growth
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
